Relapsed or Refractory Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Renal cell carcinoma (RCC) represents the predominant form of kidney cancer, constituting approximately 90% of all renal malignancies. Several factors, including tumor stage at diagnosis, patient age, overall health, and tumor mutation profiles, influence the prognosis of RCC. Refractory or relapsed RCC is observed in 20% to 30% of patients. Although the 5-year overall survival rate for RCC patients is approximately 75%, the median survival for those with refractory or relapsed disease is only 19 to 37 months, underscoring the necessity for efficacious later-line treatments. The management of advanced RCC is particularly challenging and necessitates a comprehensive understanding of the evolving treatment landscape. Various therapeutic agents, including vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR inhibitors, have been approved for treating advanced RCC.

Thelansis’s “Relapsed or Refractory Renal Cell Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Renal Cell Carcinoma (RCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Relapsed or Refractory Renal Cell Carcinoma (RCC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Relapsed or Refractory Renal Cell Carcinoma (RCC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Relapsed or Refractory Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033